Our advantage is the high level of professionalism of the project team and the extremely rapidly developing areas of the pharma genetics, which has recently received extraordinary growth in all areas of medicine.
The project PHARMAGENOME is a touch point with investors rapidly growing market of using human genome for mere effective medical treatment of patients.
Q3 2017
Q1 2018
May 2018
Q4 2018
May 2019
Q3 2019
Q2 2020
Q4 2020
Verified 0%
Attention. There is a risk that unverified members are not actually members of the team
This offer is based solely on information provided by the offeror and other publicly available sources.
The token sale or exchange event is completely independent of ICOholder. ICOholder is not involved in any way, including technical support or promotion.
We list token sales from entities with which we have no relationship to help users track overall activity within the token sector. This information is not intended as advice, and you should seek professional or specialist guidance or conduct your own due diligence before making any decisions based on our content.
Any terms and conditions regarding token acquisition are solely between contributors and the token issuer. ICOholder is not the seller of these tokens.
ICOholder is not legally responsible for any representations made by third parties about any token sale. Any claims for breach of contract must be directed against the listed token issuing entity.
If you have concerns about the nature, legality, or propriety of a token sale or the involved individuals, please contact info@icoholder.com with detailed information.